 |
|
|
| |
Assessing depression's impact on neurocognitive performance in the NAMACO study
|
| |
| |
Reported by Jules Levin
9TH IAS CONFERENCE ON HIV SCIENCE - PARIS, FRANCE
Download the PDF here
Galia Santos1, Isabella Locatelli1, Mélanie Métral1, Alexandre Berney1, Thanh Doco Lecompte2, Alexandra Calmy2, Helen Kovari3, Philip Tarr4, Patrick Schmid5, Ursi Kunze4, Isaure Nadin2, Klemens Gutbrod6, Peter Brugger3, Katharine Darling1, Renaud Du Pasquier1, Matthias Cavassini1 and the NAMACO study group 1Lausanne University Hospital, 2Geneva University Hospitals, 3University Hospital Zurich, University of Zurich, 4Kantonsspital Baselland, University of Basel, 5St. Gallen Canton Hospital, 6University Hospital of Bern
IAS: Depression, Brain Changes & cART in HIV+ / Role of basal ganglia in depression in HIV-infected individuals - (08/03/17)
from Jules: age of participants: 53 median [49-59] - 34% of patients have neurocognitive impairment, see Table 2; 28% have depression, 9.5% severe depression; in Table 3 depression appears associated with cognitive impairment.
|
| |
|
|
|
|
|
